Oral Vitiligo Drug Showed Promise in Phase 3 Trials
Pfizer reported that study participants saw improvements in skin repigmentation compared to placebo.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Do you prefer oral medication over topical creams for treating long-term skin conditions?
Pfizer announced positive phase 3 results for its oral drug Litfulo in patients with nonsegmental vitiligo, showing significant improvements in facial and body skin pigmentation. The company now plans to pursue regulatory approval from the FDA and the European Medicines Agency.
Why it matters
Current vitiligo therapies are primarily topical, which limits the total amount of body surface area that can be treated effectively. An oral systemic option could potentially offer a new treatment pathway for patients with more widespread disease.
In the Tranquillo 2 and Tranquillo phase 3 trials, researchers tested 100-mg and 50-mg doses of Litfulo against a placebo. Participants receiving the 100-mg dose saw 21.86% facial repigmentation and 13.02% total body pigmentation improvement, significantly outperforming placebo groups.
The players
Pfizer
A global pharmaceutical company developing treatments for dermatology, oncology, and inflammatory conditions.
Incyte
A biotechnology company that manufactures the topical vitiligo treatment Opzelura.
AbbVie
A biopharmaceutical company that produces the oral JAK inhibitor Rinvoq, which is approved for vitiligo in the European Union.
The details
Litfulo is a Janus kinase (JAK) inhibitor that works systemically to modulate the immune response, which in vitiligo involves the destruction of pigment-producing cells. By targeting this pathway, the medication aims to stabilize or reverse the loss of pigment. Participants reported a meaningful reduction in disease severity by week 24, with continued noticeability improvements noted by week 52.
Timeline
July 2026: Pfizer posted topline results for the Tranquillo studies.
Late summer 2026: Rinvoq received vitiligo approval in the European Union.
October 2, 2026: Pfizer affirmed plans to apply for regulatory review.
Week 24: Meaningful benefit reported in clinical trials.
Week 52: Patients noted reduced disease noticeability.
Health Landscape
The potential approval of Litfulo marks a shift toward systemic oral therapies in a market historically dominated by topical agents like Opzelura. This trend reflects the evolving landscape of dermatology where targeted JAK inhibition is increasingly studied for chronic autoimmune pigment loss.
If you are managing vitiligo, discuss the current standard of care and emerging treatment modalities with your dermatologist. Ask if systemic options currently in trial or recently approved in other markets may eventually be appropriate for your specific clinical presentation.
The takeaway
Systemic oral treatments for vitiligo represent a potential move away from the limitations of topical-only therapy. Patients interested in new options should track future regulatory announcements and consult with a specialist to review their unique treatment history and goals.
Further reading
For broader context on current clinical advancements, visit our Cancer section.
Live Poll
Do you prefer oral medication over topical creams for treating long-term skin conditions?
